Key facts
- It has raised $2.3M; the latest was Early Stage VC ($1.4M) in Aug 2025.
- Notable investors include Agoranov.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Stēto
- ·The full record, as it builds
Funding rounds
No funding rounds for Stēto are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Stēto
Developer of a diabetes remote monitoring platform designed to remove the complexity of monitoring technologies. The company's platform features the ability to analyze data, to detect diabetes, and to keep track of it, enabling doctors to have access to tools to support their patients, and to ensure care for them, and patients to control diabetes and make informed decisions.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2022
- Employees
- 7
- Website
- steto.care/
- Ownership
- Privately Held (backing)
Stēto doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Stēto shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Stēto in its N-PORT filings yet. We sweep new filings monthly.